GlassScriptPhysician profile
Monica Lynn Shaffer
NPI 1902034606
$1,541.75
in general payments reported to CMS, 2019-2025
17 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $269 · 2022: $269 · 2023: $473 · 2024: $277 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $502.44 | 2022-2025 | |
| Novo Nordisk INC | $197.36 | 2022-2025 | Wegovy |
| Amarin Pharma, INC. | $168.81 | 2021-2022 | |
| Lilly USA, LLC | $111.09 | 2021-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $105.42 | 2022-2025 | Brilinta, Flumist Quadrivalent, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $79.53 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.34 | 2023-2025 | Xifaxan |
| Pfizer INC. | $53.07 | 2023-2025 | |
| Amgen INC. | $46.75 | 2021-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.73 | 2021-2024 | Tradjenta, Jardiance |
| Astellas Pharma US INC | $33.27 | 2025 | Veozah |
| Abbott Laboratories | $31.88 | 2024-2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $23.01 | 2024 | Keveyis |
| Glaxosmithkline, LLC. | $21.41 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.04 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $16.07 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $13.53 | 2023 | Onzetra Xsail, Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.